奥希替尼联合放化疗对晚期非小细胞肺癌患者肿瘤标志物的影响

Effect of osimertinib combined with chemoradiotherapy on tumor markers in advanced non-small cell lung cancer patients

目的探讨奥希替尼联合放化疗对晚期非小细胞肺癌患者肿瘤标志物的影响。方法依据治疗方式的不同将80例晚期NSCLC患者分为对照组和观察组,每组40例,对照组患者给予放化疗治疗,观察组患者给予奥希替尼联合放化疗治疗。比较两组患者血清肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、不良反应发生情况和随访1年预后情况。结果治疗后,两组患者血清CA125、CEA、CYFRA21-1水平均低于本组治疗前,且观察组患者血清CA125、CEA、CYFRA21-1水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)水平和CD4~+/CD8~+均高于对照组,差异均有统计学意义(P<0.05)。观察组患者的1年生存率为80.00%,高于对照组患者的55.00%(P<0.05);观察组患者的1年无进展生存率为62.50%,高于对照组患者的40.00%(P<0.05);观察组患者不良反应总发生率为22.50%,低于对照组患者的45.00%(P<0.05)。结论奥希替尼联合放化疗治疗晚期NSCLC患者,可有效降低肿瘤标志物水平,改善免疫功能,提高治疗安全性,有助于改善患者的预后。

Objective To investigate the effect of osimertinib combined with chemoradiotherapy on tumor markers in patients with advanced non-small cell lung cancer(NSCLC).Method A total of 80 patients with advanced NSCLC were divided into control group and observation group according to different treatment methods,with 40 cases in each group.The patients in the control group were given chemoradiotherapy,and the patients in the observation group were given osimertinib combined with chemoradiotherapy.Serum tumor markers[carbohydrate antigen 125(CA125),carcinoembry-onic antigen(CEA),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)],T lymphocyte subsets(CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)),the occurrence of adverse events,and the prognosis after one-year follow-up were compared between the two groups.Result After the treatment,the levels of serum CA125,CEA,and CYFRA21-1 in the two groups were low-er than those before the treatment,and the serum levels of CA125,CEA,and CYFRA21-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+,CD4^(+),and CD4^(+)/CD8^(+) in both groups were lower than those before the treatment,and the levels of CD3^(+),CD4^(+),and CD4+/CD8+in the observation group were higher than those in the control group,and the differences were sta-tistically significant(P<0.05).The one-year survival rate of the observation group was 80.00%,which was higher than 55.00%of the control group(P<0.05),the one-year progression-free survival rate was 62.50%,which was higher than 40.00%of the control group(P<0.05),and the total incidence of adverse events was 22.50%,which was lower than 45.00%in the control group(P<0.05).Conclusion Osimertinib combined with chemoradiotherapy in the treatment of advanced NSCLC could effectively reduce the levels of tumor markers,improve immune function and safety,and help im-prove the prognosis of patients.